NEWS HIGHLIGHTS
Published Studies Related to Methergine (Methylergonovine)
Efficacy and tolerability of intravenous methylergonovine in migraine female patients attending the emergency department: a pilot open-label study. [2009.11.08]
BACKGROUND: Methylergonovine is an ergot alkaloid widely used in postpartum women. It is also an active metabolite of methysergide and previous studies suggest that it could be effective against refractory headache and cluster headache. The purpose of the present study was to assess the potential therapeutic effectiveness of methylergonovine in the emergency treatment of severe migraine... CONCLUSION: Although limited by the non-controlled design of the study, our data suggest that intravenous methylergonovine can be an effective and safe drug in the management of severe migraine attacks in the emergency room.
Postpartum severe sinus bradycardia following methylergonovine administration. [2008.09]
The case is reported of a 30-year-old multigravida, with insignificant history and stable vital signs, admitted to the labour room for normal vaginal delivery of twins... Intravenous atropine sulphate following methylergonovine maleate administration may lead to severe hypertension and tachycardia.
Clinical Trials Related to Methergine (Methylergonovine)
Reduction of Endometritis After Cesarean Section With the Routine Use of Methergine [Recruiting]
Endomyometritis is an "infection in the uterus". It can occur in up to 1 out of 5 women
having unplanned cesarean deliveries. Antibiotics are routinely given at the time of
Cesarean delivery, but the infection in the uterus can still occur. When endomyometritis
occurs it can prolong the woman's stay in the hospital after birth, slow down her recovery
time at home, and increase medical costs. Methergine is a medication that is routinely used
to stop uterine hemorrhage (excessive bleeding from the uterus) that sometimes happens after
delivery. Methergine works by contracting (tightening) the uterus. These contractions also
help the uterus to expel or remove parts of the placenta that increase the chance of
developing a uterine infection.
This research study is being done to learn if routine use of Methergine can lower the
chances of developing a uterine infection after cesarean delivery. Half of the women in this
study will receive Methergine for a few days during their hospitalization after cesarean
delivery. The other half of the women will not routinely receive Methergine.
Oxytocin And Uterotonic Agent Use For Cesarean Delivery [Recruiting]
The central objective of this study will be to evaluate a standardized, evidence-based
regimen versus a conventional regimen for uterotonic drug dosing during cesarean delivery
The investigators primary hypothesis is that the proposed uterotonic drug regimen, when
compared to conventional dosing regimen, during cesarean delivery will:
1. Reduce the overall amount of oxytocin and other uterotonic agents used to obtain
satisfactory uterine tone.
Secondary outcomes to be evaluated will be:
1. Reduce the side effects associated with uterotonic drug use
2. Reduce the time to establishment and maintenance of adequate uterine tone
Reports of Suspected Methergine (Methylergonovine) Side Effects
Accidental Drug Intake by Child (13),
Vomiting (11),
Abdominal Pain (8),
Maternal Exposure During Pregnancy (8),
Accidental Exposure (8),
Abdominal Discomfort (6),
Malaise (6),
Pallor (5),
Feeling Hot (5),
Hallucination (5), more >>
|
